Acumen Pharmaceuticals Files Q1 2025 10-Q

Ticker: ABOS · Form: 10-Q · Filed: May 13, 2025 · CIK: 1576885

Acumen Pharmaceuticals, INC. 10-Q Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

Acumen Pharma's Q1 2025 10-Q is in. Check financials.

AI Summary

Acumen Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the biological products sector. Its principal executive offices are located at 427 Park St., Charlottesville, VA.

Why It Matters

This filing provides investors with a quarterly update on Acumen Pharmaceuticals' financial health and operational status, crucial for understanding its performance in the biotechnology sector.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new disclosures.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Acumen Pharmaceuticals, Inc.?

Acumen Pharmaceuticals, Inc. is primarily involved in the Biological Products sector, specifically excluding diagnostic substances, as indicated by its SIC code [2836].

Where are Acumen Pharmaceuticals, Inc.'s principal executive offices located?

The company's principal executive offices are located at 427 Park St., Charlottesville, VA 22902.

What is the SEC file number for Acumen Pharmaceuticals, Inc.?

The SEC file number for Acumen Pharmaceuticals, Inc. is 001-40551.

For what period is this 10-Q filing?

This 10-Q filing is for the period ending March 31, 2025.

When was this 10-Q filing submitted to the SEC?

This 10-Q filing was submitted to the SEC on May 13, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Acumen Pharmaceuticals, Inc. (ABOS).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing